Cargando…
Homologous recombination proficiency in ovarian and breast cancer patients
Homologous recombination and DNA repair are important for genome maintenance. Genetic variations in essential homologous recombination genes, including BRCA1 and BRCA2 results in homologous recombination deficiency (HRD) and can be a target for therapeutic strategies including poly (ADP-ribose) poly...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555001/ https://www.ncbi.nlm.nih.gov/pubmed/34711195 http://dx.doi.org/10.1186/s12885-021-08863-9 |
_version_ | 1784591892762066944 |
---|---|
author | Creeden, Justin Fortune Nanavaty, Nisha S. Einloth, Katelyn R. Gillman, Cassidy E. Stanbery, Laura Hamouda, Danae M. Dworkin, Lance Nemunaitis, John |
author_facet | Creeden, Justin Fortune Nanavaty, Nisha S. Einloth, Katelyn R. Gillman, Cassidy E. Stanbery, Laura Hamouda, Danae M. Dworkin, Lance Nemunaitis, John |
author_sort | Creeden, Justin Fortune |
collection | PubMed |
description | Homologous recombination and DNA repair are important for genome maintenance. Genetic variations in essential homologous recombination genes, including BRCA1 and BRCA2 results in homologous recombination deficiency (HRD) and can be a target for therapeutic strategies including poly (ADP-ribose) polymerase inhibitors (PARPi). However, response is limited in patients who are not HRD, highlighting the need for reliable and robust HRD testing. This manuscript will review BRCA1/2 function and homologous recombination proficiency in respect to breast and ovarian cancer. The current standard testing methods for HRD will be discussed as well as trials leading to approval of PARPi’s. Finally, standard of care treatment and synthetic lethality will be reviewed. |
format | Online Article Text |
id | pubmed-8555001 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-85550012021-10-29 Homologous recombination proficiency in ovarian and breast cancer patients Creeden, Justin Fortune Nanavaty, Nisha S. Einloth, Katelyn R. Gillman, Cassidy E. Stanbery, Laura Hamouda, Danae M. Dworkin, Lance Nemunaitis, John BMC Cancer Review Homologous recombination and DNA repair are important for genome maintenance. Genetic variations in essential homologous recombination genes, including BRCA1 and BRCA2 results in homologous recombination deficiency (HRD) and can be a target for therapeutic strategies including poly (ADP-ribose) polymerase inhibitors (PARPi). However, response is limited in patients who are not HRD, highlighting the need for reliable and robust HRD testing. This manuscript will review BRCA1/2 function and homologous recombination proficiency in respect to breast and ovarian cancer. The current standard testing methods for HRD will be discussed as well as trials leading to approval of PARPi’s. Finally, standard of care treatment and synthetic lethality will be reviewed. BioMed Central 2021-10-28 /pmc/articles/PMC8555001/ /pubmed/34711195 http://dx.doi.org/10.1186/s12885-021-08863-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Creeden, Justin Fortune Nanavaty, Nisha S. Einloth, Katelyn R. Gillman, Cassidy E. Stanbery, Laura Hamouda, Danae M. Dworkin, Lance Nemunaitis, John Homologous recombination proficiency in ovarian and breast cancer patients |
title | Homologous recombination proficiency in ovarian and breast cancer patients |
title_full | Homologous recombination proficiency in ovarian and breast cancer patients |
title_fullStr | Homologous recombination proficiency in ovarian and breast cancer patients |
title_full_unstemmed | Homologous recombination proficiency in ovarian and breast cancer patients |
title_short | Homologous recombination proficiency in ovarian and breast cancer patients |
title_sort | homologous recombination proficiency in ovarian and breast cancer patients |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555001/ https://www.ncbi.nlm.nih.gov/pubmed/34711195 http://dx.doi.org/10.1186/s12885-021-08863-9 |
work_keys_str_mv | AT creedenjustinfortune homologousrecombinationproficiencyinovarianandbreastcancerpatients AT nanavatynishas homologousrecombinationproficiencyinovarianandbreastcancerpatients AT einlothkatelynr homologousrecombinationproficiencyinovarianandbreastcancerpatients AT gillmancassidye homologousrecombinationproficiencyinovarianandbreastcancerpatients AT stanberylaura homologousrecombinationproficiencyinovarianandbreastcancerpatients AT hamoudadanaem homologousrecombinationproficiencyinovarianandbreastcancerpatients AT dworkinlance homologousrecombinationproficiencyinovarianandbreastcancerpatients AT nemunaitisjohn homologousrecombinationproficiencyinovarianandbreastcancerpatients |